Moreover, pediatric ALL and AML were most affected by deep deletions in PID-related genes, with an overall alteration frequency of 66% and 57% across patients in their respective cancer cohorts and deep deletions making up 52% and 44% of the overall frequency, respectively (Figure 4B). The gene discussed is MTA2; the disease is acute lymphoblastic leukemia.